▲ +266.88% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Applied Genetic Technologies in the last 3 months. The average price target is $15.81, with a high forecast of $30.00 and a low forecast of $7.50. The average price target represents a 266.88% upside from the last price of $4.31.
The current consensus among 8 investment analysts is to buy stock in Applied Genetic Technologies. This Buy consensus rating has held steady for over two years.
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.